🔗 Share this article

Given that the US continues making unprecedented adjustments to its vaccine schedules, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by casting doubt on Covid shots during the pandemic and has zeroed in on alleged fatalities after Covid immunization in her short tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Schedule

Public health authorities planned to announce radical changes to the childhood immunization program earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US out of step with a large portion of the international standard with no evidence for improved outcomes. This reveal has been pushed back until the next year.

Instead of Vinay Prasad, Høeg is scheduled to present at the meeting. She was just designated acting director of the FDA’s CDER, the fifth appointee to lead the division this year.

Consolidating Power at the Agency

This interim role may indicate a closer partnership between the drug and vaccine centers as Høeg and Prasad solidify control at the agency – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing some pediatric immunization guidelines in the US so as to align more in line with the Danish model, a society with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

To date public appearances, she has kept her attention on immunizations – usually the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent experience in medication creation, approval processes or management, which has been customary for former directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a large organization. She lacks background in pharmaceutical oversight.”

Former directors of the center would “understand legal statutes and the underlying principles of drug development”, commented Janet Woodcock. “Clearly, she doesn’t have the type of experience that previous people who ran CBER have had.”

This division has an vast portfolio at the FDA, the former commissioner emphasized.

“Everybody just pays attention on the new drug program, but the generic program clears thousands of generic drugs. There is also a biosimilars program, over-the-counter program and so forth, and all of those must be looked after,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial leadership aspect to the role, which oversees more than 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” Woodcock added.

Official Statement and Controversial Initiatives

Regarding questions about Høeg’s qualifications and whether this selection represents more teamwork among FDA leaders on immunizations, a press secretary responded that the “questions rely on incorrect premises”.

“Her resume is consistent with the functions of her position,” the representative explained, pointing to the months Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the agency head's new priority voucher program, a controversial rapid therapy clearance system that allegedly troubled her predecessors. “By what process are these medications being chosen for this voucher program? Who makes the choices?” Howard said. “There is a lot of secrecy going on at the agency right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards more relaxed oversight of pharmaceuticals, aside from vaccines.”

Public Track Record on Immunizations

With immunizations, Høeg has a clearer, if problematic, history, some experts have noted. She authored a analysis using unconfirmed crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “policy goals” for the incoming government included revising guidelines for new vaccines and discontinuing “optional” vaccines, she remarked after the election on a online show. At the FDA, Høeg has allegedly proposed barring adolescent males from obtaining Covid vaccines.

“She’s an thorough dogmatist who begins with her beliefs and works backwards to retrofit the evidence in a highly misleading, untruthful fashion,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg joined other dissenters, {like|